-+ 0.00%
-+ 0.00%
-+ 0.00%

Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029

Benzinga·10/01/2026 20:51:12
Listen to the news

Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88 million transaction. The Company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering.